Abstract Background Cigarette smoking is one of the leading causes of early death. UK-licensed stop-smoking medicines include Varenicline [Champix], Bupropion [Zyban], Nicotine Replacement Therapy [NRT], and one electronic cigarette (E-cigarette) model; however, there is ongoing debate regarding their neuropsychiatric safety.Methodology: We conducted systematic reviews and network meta-analyses of RCTs of medicines delivered as monotherapy and in combination treatment (e.g. Varenicline+NRT) with control groups. Studies published before March 2017 were identified from 8 databases. The primary composite safety outcome was serious adverse events (SAEs) and secondary composite outcomes were major adverse neuropsychiatric events (MANEs) and major adverse cardiovascular events (MACEs). The primary effectiveness outcome was sustained smoking cessation abstinence (≥ 6 months, bio-verified). Results We screened 10,779 records and analysed 334 and 346 RCTs for safety and effectiveness outcomes, respectively. We found that Bupropion increased the odds of SAEs (OR=1.31, 95% CI 1.06-1.60) but reduced the odds of MANEs (0.62, 0.42-0.87) compared to placebo, whereas E-Cigarette increased odds of SAEs compared to placebo (2.34, 1.09-5.16). No treatment increased the odds of MACEs compared to placebo. Regarding effectiveness, smokers randomised to Bupropion (1.65, 1.39-1.95), Varenicline (2.75, 2.29 to 3.29), Varenicline+NRT (5.58, 2.25-14.0) or Varenicline+Bupropion (2.80, 1.15-6.96), alongside E-Cigarette users (2.75, 1.26-6.11), were more likely to achieve sustained abstinence than smokers treated with placebo. Conclusions Combination treatment with varenicline and NRT (unlicensed in the UK) is most likely to be effective at achieving sustained abstinence from smoking. E-cigarettes for smoking cessation showed promise, but increased odds for a SAE based on few studies. External funding details This project presents independent research which was funded by the National Institute for Health Research Health Technology Assessment Programme (project number NIHR HTA 15/58/18).
Abstract Background Cigarette smoking is one of the leading causes of early death. UK-licensed stop-smoking medicines include Varenicline [Champix], Bupropion [Zyban], Nicotine Replacement Therapy [NRT], and one electronic cigarette (E-cigarette) model; however, there is ongoing debate regarding their neuropsychiatric safety.Methodology: We conducted systematic reviews and network meta-analyses of RCTs of medicines delivered as monotherapy and in combination treatment (e.g. Varenicline+NRT) with control groups. Studies published before March 2017 were identified from 8 databases. The primary composite safety outcome was serious adverse events (SAEs) and secondary composite outcomes were major adverse neuropsychiatric events (MANEs) and major adverse cardiovascular events (MACEs). The primary effectiveness outcome was sustained smoking cessation abstinence (≥ 6 months, bio-verified). Results We screened 10,779 records and analysed 334 and 346 RCTs for safety and effectiveness outcomes, respectively. We found that Bupropion increased the odds of SAEs (OR=1.31, 95% CI 1.06-1.60) but reduced the odds of MANEs (0.62, 0.42-0.87) compared to placebo, whereas E-Cigarette increased odds of SAEs compared to placebo (2.34, 1.09-5.16). No treatment increased the odds of MACEs compared to placebo. Regarding effectiveness, smokers randomised to Bupropion (1.65, 1.39-1.95), Varenicline (2.75, 2.29 to 3.29), Varenicline+NRT (5.58, 2.25-14.0) or Varenicline+Bupropion (2.80, 1.15-6.96), alongside E-Cigarette users (2.75, 1.26-6.11), were more likely to achieve sustained abstinence than smokers treated with placebo. Conclusions Combination treatment with varenicline and NRT (unlicensed in the UK) is most likely to be effective at achieving sustained abstinence from smoking. E-cigarettes for smoking cessation showed promise, but increased odds for a SAE based on few studies. External funding details This project presents independent research which was funded by the National Institute for Health Research Health Technology Assessment Programme (project number NIHR HTA 15/58/18).
By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS). USER TERMS AND CONDITIONS | PRIVACY POLICY
Cookie Settings
Accept Terms & all Cookies
Anonymous User Privacy Preferences
Strictly Necessary Cookies (Always Active)
MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.
Performance Cookies
Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.
